Byondis Initiates Phase I Study of Next Generation Antibody-

/PRNewswire/ -- Byondis B.V., an independent, clinical stage Dutch biopharmaceutical company creating precision medicines, today announced that the first...

Related Keywords

Italy , Netherlands , Nijmegen , Gelderland , Belgium , Dutch , Prnewswire Byondis , Wim Dokter , Jan Schellens , Us Food Drug Administration , European Medicines Agency , Conjugation Technology , Widely Overexpressed , Uses Proprietary Technologies Designed , Enhance Efficacy , Human Dose Escalation , Expansion Trial With , Antibody Drug Conjugate , Expressing Locally Advanced , Metastatic Solid , Byondis Chief Medical Officer Jan Schellens , Byondis Chief Scientific Officer Wim Dokter , Biologics License Application , Drug Administration , Marketing Authorization Application , Dose Escalation , Maximum Tolerated Dose , Recommended Dose , Next Generation Antibody Drug , Proprietary Linker Drug , Site Specific Conjugation , Good Manufacturing Practice , Byondisbv ,